Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy.

被引：0
|
作者：
Ghidini, Michele
Hahne, Jens Claus
Senti, Chiara
Tomasello, Gianluca
Ratti, Margherita
Heide, Timon
Garrone, Ornella
Cortellini, Alessio
Passalacqua, Rodolfo
Valeri, Nicola
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Med Oncol, Milan, Italy
[2] Inst Canc Res, London, England
[3] Hosp Cremona, Div Med Oncol, ASST Cremona, Cremona, Italy
[4] Human Technopole, Milan, Italy
[5] Imperial Coll London, Div Surg & Canc, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
175
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [41] Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).
    Lee, Jenny H. J.
    Menzies, Alexander M.
    Carlino, Matteo S.
    Kefford, Richard
    Scolyer, Richard A.
    Long, Georgina V.
    Rizos, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Clinical utility of circulating tumor DNA (ctDNA) in advanced and metastatic breast cancer
    Austin, Laura K.
    Jaslow, Rebecca
    Avery, Tiffany
    Fortina, Paolo
    Sebisanovic, Dragan
    Siew, LaiMun
    Zapanta, Aubrey
    Talasaz, AmirAli
    Cristofanilli, Massimo
    CANCER RESEARCH, 2015, 75
  • [43] Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
    Nakamura, Yoshiaki
    Yoshino, Takayuki
    ONCOLOGIST, 2018, 23 (11): : 1310 - 1318
  • [44] Circulating tumor (ct) DNA captures intrapatient heterogeneity in metastatic colorectal (mCRC) patients (pts) progressing to FOLFIRI plus panitumumab
    Vidal, J.
    Vieitez, J. M.
    Paez, D.
    Santos, C.
    Falco, E.
    Lopez Lopez, C.
    Valladares-Ayerbes, M.
    Robles, L.
    Garcia-Alfonso, P.
    Duran Ogaya, G.
    Azuara, D.
    Dalmeses, A.
    Bellosillo Paricio, B.
    Capella, G.
    Salazar, R.
    Aranda Aguilar, E.
    Montagut, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Increasing adipose burden in young men with metastatic testicular cancer following front-line cytotoxic chemotherapy.
    Arora, Karan Kumar
    Kato, Caroline
    Batra, Kunnal
    Mullane, Michael Russell
    Lad, Thomas E.
    Master, Viraj A.
    Psutka, Sarah P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [46] Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy.
    Grothe, W
    Arnold, D
    Peinert, S
    Voigt, W
    Loeffler, LM
    Siewczynski, R
    Steps, G
    Boehme, J
    Graeven, U
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 288S - 288S
  • [47] Circulating tumor DNA (ctDNA) in metastatic uveal melanoma (MUM): Correlation with outcome in 87 patients (pts) from Institut Curie
    Piperno-Neumann, S.
    Madic, J.
    Mariani, P.
    Rampanou, A.
    Servois, V.
    Bidard, F. C.
    Milder, M.
    Cassoux, N.
    Desjardins, L.
    Stern, M. H.
    Lantz, O.
    ACTA OPHTHALMOLOGICA, 2013, 91
  • [48] Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
    Sunakawa, Y.
    Usher, J.
    Satake, H.
    Jaimes, Y.
    Miyamoto, Y.
    Nakamura, M.
    Kataoka, M.
    Shiozawa, M.
    Takagane, A.
    Terazawa, T.
    Watanabe, T.
    Ishigure, K.
    Tanaka, C.
    Sekikawa, T.
    Takeuchi, M.
    Fujii, M.
    Danenberg, K.
    Danenberg, P. V.
    Lenz, H-J.
    Ichikawa, W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome
    Teufel, M.
    Kalmus, J.
    Rutstein, M.
    Koechert, K.
    Seidel, H.
    Reischl, J.
    Skubula, A.
    Vonk, R.
    Wilhelm, S.
    Kobina, S.
    Qin, S.
    Xu, R.
    Kim, T. W.
    Li, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S332 - S332
  • [50] Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Maurice-Dror, Corinne
    Fonseca, Nicolette
    Herberts, Cameron
    Fan, William
    Wyatt, Alexander W.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345